

Thomas O Carpenter

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7816953/publications.pdf>

Version: 2024-02-01

88
papers

6,126
citations

71102

41
h-index

71685

76
g-index

95
all docs

95
docs citations

95
times ranked

4192
citing authors

#	ARTICLE	IF	CITATIONS
1	Sustained Efficacy and Safety of Burosumab, a Monoclonal Antibody to FGF23, in Children With X-Linked Hypophosphatemia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 813-824.	3.6	36
2	Novel PHEX gene locus-specific database: Comprehensive characterization of vast number of variants associated with X-linked hypophosphatemia (XLH). <i>Human Mutation</i> , 2022, 43, 143-157.	2.5	18
3	Different elemental infant formulas show equivalent phosphorus and calcium bioavailability in healthy volunteers. <i>Nutrition Research</i> , 2021, 85, 71-83.	2.9	3
4	Novel homozygous variant in BMP1 associated with a rare osteogenesis imperfecta phenotype. <i>Osteoporosis International</i> , 2021, 32, 1239-1244.	3.1	1
5	Serum Levels of Lipocalin Are Lower in Adolescents With X-Linked Hypophosphatemia. <i>Journal of the Endocrine Society</i> , 2021, 5, A27-A27.	0.2	1
6	25-OHD response to vitamin D supplementation in children: effect of dose but not GC haplotype. <i>European Journal of Endocrinology</i> , 2021, 185, 333-342.	3.7	3
7	Phosphorus bioaccessibility measured in four amino acid-based formulas using in-vitro batch digestion translates well into phosphorus bioavailability in mice. <i>Nutrition</i> , 2021, 89, 111291.	2.4	0
8	Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension. <i>RMD Open</i> , 2021, 7, e001714.	3.8	26
9	Case 32-2021: A 14-Year-Old Girl with Swelling of the Jaw and Hypercalcemia. <i>New England Journal of Medicine</i> , 2021, 385, 1604-1613.	27.0	4
10	Severity of reduced bone mineral density and risk of fractures in long-term survivors of childhood leukemia and lymphoma undergoing guideline-recommended surveillance for bone health. <i>Cancer</i> , 2020, 126, 202-210.	4.1	13
11	Human Heterozygous ENPP1 Deficiency Is Associated With Early Onset Osteoporosis, a Phenotype Recapitulated in a Mouse Model of Enpp1 Deficiency. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 528-539.	2.8	40
12	Phosphorus homeostasis and related disorders. , 2020, , 469-507.		1
13	Frequent overexpression of klotho in fusion-negative phosphaturic mesenchymal tumors with tumorigenic implications. <i>Modern Pathology</i> , 2020, 33, 858-870.	5.5	17
14	Relationship of Total and Free 25-Hydroxyvitamin D to Biomarkers and Metabolic Indices in Healthy Children. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e1631-e1640.	3.6	9
15	Long-Term Follow-up of Hypophosphatemic Bone Disease Associated With Elemental Formula Use: Sustained Correction of Bone Disease After Formula Change or Phosphate Supplementation. <i>Clinical Pediatrics</i> , 2020, 59, 1080-1085.	0.8	6
16	Growth Curves for Children with X-linked Hypophosphatemia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 3243-3249.	3.6	26
17	Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 432.	7.4	162
18	Burosumab for the Treatment of Tumor-Induced Osteomalacia. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 627-635.	2.8	87

#	ARTICLE	IF	CITATIONS
19	Response of the ENPP1-Deficient Skeletal Phenotype to Oral Phosphate Supplementation and/or Enzyme Replacement Therapy: Comparative Studies in Humans and Mice. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 942-955.	2.8	15
20	Reply to: Burosumab for Tumor-Induced Osteomalacia: not Enough of a Good Thing. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 2455-2456.	2.8	1
21	SUN-LB19 Novel Homozygous Mutation in BMP1 Causing Osteogenesis Imperfecta. <i>Journal of the Endocrine Society</i> , 2020, 4, .	0.2	0
22	Musculoskeletal Comorbidities and Quality of Life in ENPP1-Deficient Adults and the Response of Enthesopathy to Enzyme Replacement Therapy in Murine Models. <i>Journal of Bone and Mineral Research</i> , 2020, 37, 494-504.	2.8	12
23	Description of 5 Novel SLC34A3/NPT2c Mutations Causing Hereditary Hypophosphatemic Rickets With Hypercalciuria. <i>Kidney International Reports</i> , 2019, 4, 1179-1186.	0.8	14
24	High dose vitamin D supplementation does not rescue bone loss following Roux-en-Y gastric bypass in female rats. <i>Bone</i> , 2019, 127, 172-180.	2.9	8
25	Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period. <i>Calcified Tissue International</i> , 2019, 105, 271-284.	3.1	102
26	Rickets severity predicts clinical outcomes in children with X-linked hypophosphatemia: Utility of the radiographic Rickets Severity Score. <i>Bone</i> , 2019, 122, 76-81.	2.9	53
27	Efficacy and safety of burosumab in children aged 1-4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 189-199.	11.4	115
28	Skeletal disease in a father and daughter with a novel monoallelic WNT1 mutation. <i>Bone Reports</i> , 2018, 9, 154-158.	0.4	3
29	Burosumab Therapy in Children with X-Linked Hypophosphatemia. <i>New England Journal of Medicine</i> , 2018, 378, 1987-1998.	27.0	339
30	Rickets: The Skeletal Disorders of Impaired Calcium or Phosphate Availability. , 2018, , 497-524.		2
31	A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 1383-1393.	2.8	229
32	Unexpected widespread hypophosphatemia and bone disease associated with elemental formula use in infants and children. <i>Bone</i> , 2017, 97, 287-292.	2.9	50
33	CYP24A1 loss of function: Clinical phenotype of monoallelic and biallelic mutations. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2017, 173, 337-340.	2.5	48
34	Rickets. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17101.	30.5	131
35	Pigment epithelium-derived factor restoration increases bone mass and improves bone plasticity in a model of osteogenesis imperfecta type VI via Wnt3a blockade. <i>FASEB Journal</i> , 2016, 30, 2837-2848.	0.5	28
36	Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia. <i>Bone Reports</i> , 2016, 5, 158-162.	0.4	47

#	ARTICLE	IF	CITATIONS
37	Pharmacokinetics and pharmacodynamics of a human monoclonal anti-FGF23 antibody (KRN23) in the first multiple ascending-dose trial treating adults with X-linked hypophosphatemia. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 176-185.	2.0	38
38	Characterization of FN1-FGFR1 and novel FN1-FGF1 fusion genes in a large series of phosphaturic mesenchymal tumors. <i>Modern Pathology</i> , 2016, 29, 1335-1346.	5.5	139
39	An Unusual Case of Rickets and How Whole Exome Sequencing Helped to Correct a Diagnosis. <i>AACE Clinical Case Reports</i> , 2016, 2, ee278-ee283.	1.1	1
40	Hypophosphatemia promotes lower rates of muscle ATP synthesis. <i>FASEB Journal</i> , 2016, 30, 3378-3387.	0.5	70
41	Characterization of additional vitamin D binding protein variants. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2016, 159, 54-59.	2.5	6
42	Population pharmacokinetic and pharmacodynamic analyses from a 4-month intradose escalation and its subsequent 12-month dose titration studies for a human monoclonal anti-FGF23 antibody (KRN23) in adults with X-linked hypophosphatemia. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 429-438.	2.0	19
43	Hypophosphatemic Rickets: Lessons from Disrupted FGF23 Control of Phosphorus Homeostasis. <i>Current Osteoporosis Reports</i> , 2015, 13, 88-97.	3.6	53
44	Prolonged Correction of Serum Phosphorus in Adults With X-Linked Hypophosphatemia Using Monthly Doses of KRN23. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 2565-2573.	3.6	141
45	A Practical Clinical Approach to Paediatric Phosphate Disorders. <i>Endocrine Development</i> , 2015, 28, 134-161.	1.3	12
46	Contemporary Medical and Surgical Management of X-linked Hypophosphatemic Rickets. <i>Journal of the American Academy of Orthopaedic Surgeons</i> , The, 2015, 23, 433-442.	2.5	42
47	Association between serum 25-hydroxyvitamin D level and pulmonary exacerbations in cystic fibrosis. <i>Pediatric Pulmonology</i> , 2015, 50, 441-446.	2.0	39
48	Conventional Therapy in Adults With X-Linked Hypophosphatemia: Effects on Enthesopathy and Dental Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 3625-3632.	3.6	106
49	Effect of Paricalcitol on Circulating Parathyroid Hormone in X-Linked Hypophosphatemia: A Randomized, Double-Blind, Placebo-Controlled Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 3103-3111.	3.6	22
50	Mutations in SLC34A3/NPT2c Are Associated with Kidney Stones and Nephrocalcinosis. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 2366-2375.	6.1	124
51	Gastric bypass in obese rats causes bone loss, vitamin D deficiency, metabolic acidosis, and elevated peptide YY. <i>Surgery for Obesity and Related Diseases</i> , 2014, 10, 878-884.	1.2	27
52	Effect of vitamin D-binding protein genotype on the development of asthma in children. <i>Annals of Allergy, Asthma and Immunology</i> , 2014, 112, 519-524.	1.0	28
53	Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. <i>Journal of Clinical Investigation</i> , 2014, 124, 1587-1597.	8.2	264
54	Exome sequencing reveals FAM20c mutations associated with fibroblast growth factor 23-related hypophosphatemia, dental anomalies, and ectopic calcification. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 1378-1385.	2.8	144

#	ARTICLE	IF	CITATIONS
55	Vitamin D binding protein is a key determinant of 25-hydroxyvitamin D levels in infants and toddlers. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 213-221.	2.8	87
56	Rickets: The Skeletal Disorders of Impaired Calcium or Phosphate Availability. , 2013, , 357-378.		2
57	Heart Failure in Hypophosphatemic Rickets: Complications from High-Dose Phosphate Therapy. <i>Endocrine Practice</i> , 2013, 19, e8-e11.	2.1	7
58	Genetic Defect in <i>CYP24A1</i> , the Vitamin D 24-Hydroxylase Gene, in a Patient with Severe Infantile Hypercalcemia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E268-E274.	3.6	113
59	Demographic, dietary, and biochemical determinants of vitamin D status in inner-city children. <i>American Journal of Clinical Nutrition</i> , 2012, 95, 137-146.	4.7	60
60	Familial Hypophosphatemia and Related Disorders. , 2012, , 699-726.		8
61	The expanding family of hypophosphatemic syndromes. <i>Journal of Bone and Mineral Metabolism</i> , 2012, 30, 1-9.	2.7	141
62	Calcitonin Administration in X-Linked Hypophosphatemia. <i>New England Journal of Medicine</i> , 2011, 364, 1678-1680.	27.0	36
63	A clinician's guide to X-linked hypophosphatemia. <i>Journal of Bone and Mineral Research</i> , 2011, 26, 1381-1388.	2.8	476
64	Nuclear Isoforms of Fibroblast Growth Factor 2 Are Novel Inducers of Hypophosphatemia via Modulation of FGF23 and KLOTHO. <i>Journal of Biological Chemistry</i> , 2010, 285, 2834-2846.	3.4	57
65	Treatment of X-Linked Hypophosphatemia with Calcitriol and Phosphate Increases Circulating Fibroblast Growth Factor 23 Concentrations. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 1846-1850.	3.6	138
66	Circulating Levels of Soluble Klotho and FGF23 in X-Linked Hypophosphatemia: Circadian Variance, Effects of Treatment, and Relationship to Parathyroid Status. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, E352-E357.	3.6	132
67	Variations in cord 25-hydroxyvitamin D levels in Hispanic and Caucasian infants are not related to neonatal bone mineral status. <i>FASEB Journal</i> , 2010, 24, 325.4.	0.5	0
68	Survey of the Enthesopathy of X-Linked Hypophosphatemia and Its Characterization in Hyp Mice. <i>Calcified Tissue International</i> , 2009, 85, 235-246.	3.1	95
69	A translocation causing increased β -Klotho level results in hypophosphatemic rickets and hyperparathyroidism. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 3455-3460.	7.1	221
70	A novel missense mutation in SLC34A3 that causes hereditary hypophosphatemic rickets with hypercalciuria in humans identifies threonine 137 as an important determinant of sodium-phosphate cotransport in NaPi-IIc. <i>American Journal of Physiology - Renal Physiology</i> , 2008, 295, F371-F379.	2.7	70
71	Evaluation of bone and mineral disorders. <i>Pediatric Endocrinology Reviews</i> , 2007, 5 Suppl 1, 584-98.	1.2	16
72	SLC34A3 Mutations in Patients with Hereditary Hypophosphatemic Rickets with Hypercalciuria Predict a Key Role for the Sodium-Phosphate Cotransporter NaPi-IIc in Maintaining Phosphate Homeostasis. <i>American Journal of Human Genetics</i> , 2006, 78, 179-192.	6.2	422

#	ARTICLE	IF	CITATIONS
73	Surveillance for Early Detection of Aggressive Parathyroid Disease: Carcinoma and Atypical Adenoma in Familial Isolated Hyperparathyroidism Associated With a Germline HRPT2 Mutation. <i>Journal of Bone and Mineral Research</i> , 2006, 21, 1666-1671.	2.8	74
74	A Randomized Controlled Study of Effects of Dietary Magnesium Oxide Supplementation on Bone Mineral Content in Healthy Girls. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 4866-4872.	3.6	72
75	Relationships among Vitamin D Levels, Parathyroid Hormone, and Calcium Absorption in Young Adolescents. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 5576-5581.	3.6	158
76	Fibroblast Growth Factor 7: An Inhibitor of Phosphate Transport Derived from Oncogenic Osteomalacia-Causing Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 1012-1020.	3.6	136
77	Oncogenic Osteomalacia "A Complex Dance of Factors. <i>New England Journal of Medicine</i> , 2003, 348, 1705-1708.	27.0	114
78	Nutritional Rickets with Normal Circulating 25-Hydroxyvitamin D: A Call for Reexamining the Role of Dietary Calcium Intake in North American Infants. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 3539-3545.	3.6	150
79	Familial Hypophosphatemia and Related Disorders. , 2003, , 603-XVI.		12
80	Mutational Analysis and Genotype-Phenotype Correlation of the PHEX Gene in X-Linked Hypophosphatemic Rickets. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 3889-3899.	3.6	27
81	Hereditary Hypophosphatemic Rickets with Hypercalciuria Is Not Caused by Mutations in the Na/Pi Cotransporter NPT2 Gene. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 507-514.	6.1	65
82	Changes in Bone Turnover in Young Women Consuming Different Levels of Dietary Protein. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 1052-1055.	3.6	100
83	Osteocalcin Production in Primary Osteoblast Cultures Derived from Normal and Hyp Mice. <i>Endocrinology</i> , 1998, 139, 35-43.	2.8	52
84	NEW PERSPECTIVES ON THE BIOLOGY AND TREATMENT OF X-LINKED HYPOPHOSPHATEMIC RICKETS. <i>Pediatric Clinics of North America</i> , 1997, 44, 443-466.	1.8	106
85	Sonography of congenital adrenal hyperplasia due to partial deficiency of 3 β -hydroxysteroid dehydrogenase: a case report. <i>Pediatric Radiology</i> , 1997, 27, 594-595.	2.0	9
86	Secretion of a Large Molecular-Weight Form of Insulin-Like Growth Factor by a Primary Renal Tumor. <i>Medical and Pediatric Oncology</i> , 1995, 24, 392-396.	1.0	9
87	Media Calcium Attenuates Mitochondrial 1,25(OH) $_2$ D Production in Phosphorus or Vitamin D-Deprived Rats. <i>Pediatric Research</i> , 1995, 37, 726-730.	2.3	8
88	Vitamin D metabolism in chronic childhood hypoparathyroidism: Evidence for a direct regulatory effect of calcium. <i>Journal of Pediatrics</i> , 1990, 116, 252-257.	1.8	11